Everest Medicines’ Trodelvy (sacituzumab govitecan) Receives NMPA’s Approval as 2L Treatment of Metastatic Triple-Negative Breast Cancer
- The NMPA has approved Trodelvy for unresectable LA or metastatic TNBC in adult patients with ≥2 prior systemic therapies & for metastatic disease. The product is expected to be available in China in Q4’22
- The P-IIb (EVER-132-001) study met its 1EPs & showed a 38.8% ORR. The results were consistent with those from the P-III (ASCENT) study along with similar efficacy & safety in the Chinese population
- Trodelvy is being developed for TNBC & metastatic UC populations along with multiple tumors including HR+/HER2- metastatic breast cancer, m-NSCLC & SCLC, HNC & EC. Following the license agreement with Gilead, Everest gets an exclusive rights to develop, register & commercialize Trodelvy for cancer indications in Greater China & other countries
Ref: PR Newswire | Image: Everest Medicine
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].